A randomised controlled multicentre trial was performed in 160 patients with gastric ulcer, proved by endoscopy and biopsy, to compare ulcer healing with sucralfate and ranitidine (double blind double dummy design) and to assess the effect of maintenance treatment with sucralfate on ulcer recurrence (double blind placebo controlied design). The healing rates were similar with 4 g sucralfate suspension per day and 300 mg ranitidine per day (82% and 88% after 12 weeks, respectively). Of the 109 patients with healed ulcers, 92 were entered into the maintenance trial and treated with sucralfate tablets (2 g per day) or placebo tablets. Maintenance treatment with sucralfate delayed symptoms of gastric ulcer recurrence. Lifetable analysis showed significant differences between sucralfate and placebo, both after six months (p=0-018) and after 12 months (p=0044). The rates of symptom recurrences were 13% and 34% after six months and 34% and 55% after 12 months for sucralfate and placebo, respectively. The rate of asymptomatic recurrences after 12 months was similar in the two groups (9% and 10%, respectively). The recurrence rate was higher in patients who had never taken non-steroidal anti-inflammatory drugs than in those who had but had stopped on admission to the study. It was also higher in patients with recurrent ulcer and in those with scarring deformation and narrowing of the pylorus. Maintenance treatment with sucralfate slowed the appearance of symptom recurrences of gastric ulcer.
Abstract
A randomised controlled multicentre trial was performed in 160 patients with gastric ulcer, proved by endoscopy and biopsy, to compare ulcer healing with sucralfate and ranitidine (double blind double dummy design) and to assess the effect of maintenance treatment with sucralfate on ulcer recurrence (double blind placebo controlied design). The healing rates were similar with 4 g sucralfate suspension per day and 300 mg ranitidine per day (82% and 88% after 12 weeks, respectively). Of the 109 patients with healed ulcers, 92 were entered into the maintenance trial and treated with sucralfate tablets (2 g per day) or placebo tablets. Maintenance treatment with sucralfate delayed symptoms of gastric ulcer recurrence. Lifetable analysis showed significant differences between sucralfate and placebo, both after six months (p=0-018) and after 12 months (p=0044). The rates of symptom recurrences were 13% and 34% after six months and 34% and 55% after 12 months for sucralfate and placebo, respectively. The rate of asymptomatic recurrences after 12 months was similar in the two groups (9% and 10%, respectively). The recurrence rate was higher in patients who had never taken non-steroidal anti-inflammatory drugs than in those who had but had stopped on admission to the study. It was also higher in patients with recurrent ulcer and in those with scarring deformation and narrowing of the pylorus. Maintenance treatment with sucralfate slowed the appearance of symptom recurrences of gastric ulcer.
The prevention of gastric ulcer recurrences is still a major problem. While it is possible to delay the recurrence of a duodenal ulcer by initial treatment with agents such as bismuth compounds,' this is not the case for gastric ulcer.2 '8 Maintenance treatment in patients with healed gastric ulcers has been attempted with varying success using cimetidine,"2' ranitidine,'2 [22] [23] [24] [25] [26] [27] [28] pirenzepine,29 carbenoxolone,303 Caved-S, 3 antacids,'93' and also sucralfate.4 20 32-35 The results of randomised maintenance trials comparing sucralfate Maintenance treatment was started immediately after endoscopy. Outpatient visits were scheduled at two monthly intervals. During these visits weight and blood pressure were measured and the patients were interviewed concerning symptoms suggestive of a recurrence. When a recurrence was suspected endoscopy was performed. When no recurrence was suspected the patient received drugs for the next two months and a new outpatient appointment was made. In the event of epigastric distress occurring between scheduled visits, the patients were asked to contact their physician; an interim, off-schedule endoscopy was performed even if only mild or atypical symptoms were present. At the end of the one year maintenance period an endoscopy was performed on all patients who were still in the trial.
MEDICATION
The patients were randomly assigned to one of the following four treatment arms: (i) initial ulcer treatment with sucralfate followed by maintenance treatment with sucralfate; (ii) sucralfate followed by placebo; (iii) ranitidine followed by sucralfate; (iv) ranitidine followed by placebo. For each patient a complete set of medication for both phases of the study was available on admission.
Sucralfate was given for initial ulcer treatment as a suspension contained in plastic bags (5 ml of the suspension corresponded to 1 g of sucralfate) and as tablets (1 g each) in the maintenance phase. For initial ulcer treatment patients took 5 ml of the sucralfate suspension four times daily plus a ranitidine placebo, one tablet twice daily; those allocated to ranitidine treatment took one tablet (150 mg) twice daily plus a placebo sucralfate suspension (5 ml) four times daily. In this double dummy system sucralfate suspension and placebo suspension were identical in appearance, colour, and taste. The same was true for ranitidine tablets and placebo tablets. The suspension was taken a half hour before breakfast, lunch, and dinner and before going to bed. The tablets were taken together with the suspension before breakfast and before going to bed. The patients had free access to chewable tablets containing an antacid with a very low buffer capacity (3 mmol/tablet).
In the double blind maintenance treatment trial the patients who were randomised to treatment with sucralfate took a tablet containing 1 g 
Results
The results of the initial ulcer treatment trial have been published elsewhere.37 Briefly, 160 patients were admitted to the study. After the exclusion of four patients with carcinoma, 10 patients with pyloric ulceration, two patients with other protocol violations, five patients with intercurrent diseases, and five patients because of lack of compliance, a total of 134 patients could be analysed. Healing after six weeks was observed in 37 of66 patients (56%) who had been treated with sucralfate and 49 of 68 patients (72%) who had been treated with ranitidine. The cumulative healing rates after 12 weeks were 82% and 88%, respectively. The differences between the two types of treatment were not significant after six and 12 weeks.
Of the 109 patients with healed ulcer (51 of 62 patients treated with sucralfate and 58 of 66 treated with ranitidine), 92 agreed to enter the maintenance treatment trial. All 17 patients who refused gave as a reason their unwillingness to come to regular control visits and to undergo Figure) and total (symptomatic plus asymptomatic) recurrences (p=0039) (not shown separately). The difference for symptom recurrence was also significant when only the first six months of the maintenance trial were examined (p=0-018).
At 12 months, 35 (53%) of the 66 patients at risk had developed a recurrent ulcer: 15 (43%) of 35 patients in the sucralfate group and 20 (65%) of 31 patients in the placebo group. A total of 17 (23%) symptom recurrences among the 74 patients at risk were observed in the first six months, and 12 further symptom recurrences were seen during the subsequent six months (Table III) . Thus, the cumulative symptom recurrence rate in the 66 patients at risk was 44% in one year. The rates of symptom recurrence in sucralfate treated patients and placebo treated patients were 13% and 34% after six months and 34% and 55% after 12 Table IV shows the one year recurrence rates in the presence and absence of 'risk factors.' Patients with their first ulcer attack had fewer recurrences than patients with a past history of at least one recurrence. No non-steroidal antiinflammatory drug use and scarring deformation of the pylorus just reached significance as risk factors. Additional factors such as age, sex, and a past history of slow ulcer healing were not associated with a high recurrence rate.
The potential risk factors were also examined in a multiple stepwise regression analysis using the Cox proportional hazards regression model.4' This model takes into account the time of appearance of the recurrences. The type of maintenance treatment was also included in this analysis. Two factors appeared in the whole patient sample: deformation of the pylorus followed by not taking non-steroidal antiinflammatory drugs before treatment (in contrast to patients who took the drugs but stopped taking them when told that they were ulcerogenic).
Finally, the effect of risk factors was also examined using a jackknifing method. This checks the stability of the regression model and the internal consistency of the data. In a first step, 10 subsets were created; each subset was to contain approximately 90% of the entire sample of91 patients. A random selection procedure was used. The 10 subsets thus created contained 84, 82, 78, 84, 85, 88, 83, 82, 81, and 83 patients respectively. In these subsets the Cox model was again applied. In each of the 10 subsets scarring deformation and narrowing of the pylorus appeared as a factor associated with a high recurrence rate. In eight and four subsets, respectively, no consumption of non-steroidal anti-inflammatory drugs and placebo treatment after ulcer healing appeared as factors associated with a high recurrence rate.
Discussion
The main feature of this study was the double blind administration of both initial ulcer treatment and maintenance treatment with a randomisation plan extending from initiation of treatment to one year after healing. Initial ulcer treatment was given with one of two active drugs, sucralfate or ranitidine, which were shown to be equally effective in healing ulcers; after healing, maintenance treatment with either sucralfate or placebo was given.
In presenting the results of this study we have concentrated on the symptom recurrence rate since we adopted a policy of performing offschedule, diagnostic endoscopies for all symptoms, however trivial, that might have indicated ulcer recurrence; a routine endoscopy was performed only at the end of the 12 month maintenance period. This allowed us to define a hard end point for the determination of the recurrence rate; in contrast, the recurrence rate determined by regular, routine endoscopy would have been dependent on the interval between endoscopic examinations. Our approach also had the advantage of using a clinically realistic end point for the detection of ulcer recurrence; despite this, the overall recurrence rate in this study was, in fact, comparable to that reported in previous studies, without the need for regular follow up endoscopies.
Maintenance treatment with 2 g sucralfate per day in this study produced a lower rate of symptom recurrence than placebo. In a lifetable analysis differences between sucralfate and placebo were significant, both over the first six months and over the entire study period of 12 months. The rates of symptom recurrences observed with sucralfate and placebo were 13% and 34% after six months and 34% and 55% after 12 months, respectively. In contrast, the rate of asymptomatic recurrences at 12 months was similar in the two treatment groups (9% and 10%, respectively).
The symptom recurrence rate with placebo at one year (55%) was higher in this study than in previous studies. In 12 studies,39 10 12 13 15 17 22 33 41 42 43 in which patients had been treated with placebo, the symptom recurrence rate at one year was 47% (104 recurrences in 221 patients). In eight studies,3`" 4 in which patients had been followed up off treatment, the one year symptom recurrence rate was 39% (231 recurrences in 586 patients). In contrast to symptom recurrences, the proportion of patients having asymptomatic recurrences was lower in our study (17% of all recurrences) than in 13 published studies in which 77% (31%) of 245 recurrences were asymptomatic.9 11-14 15 16 In all previous studies32-31 comparing sucralfate with placebo there was at least a trend in favour of sucralfate but a significant difference was reported by only one group of investigators and that only in studies lasting for six months.3435 In other studies, sucralfate and histamine H2 receptor antagonists alone20 33 or in combination20 appeared to be equally effective. Overall, histamine antagonists such as cimetidine9 101317 48 and ranitidine'2 22 23 25 2643 appear to be superior to placebo in the prevention ofgastric ulcer relapses but, as in the case of sucralfate, most studies were too small and the large studies 12128 49 were not controlled. The present study is one of the few trials of adequate size with treatment lasting up to one year to give a conclusive result regarding the prevention of gastric ulcer relapse with maintenance drug treatment.
We have also examined whether the recurrence rate can be predicted on the basis of a patient's characteristics evaluated before initial ulcer treatment. Patients with their first ulcer attack had fewer recurrences than patients with recurrent disease. The second factor of importance is the consumption of non-steroidal antiinflammatory drugs. The role of NSAIDs in the production of gastric ulcers and their recurrence is controversial.9505' In the present study, all patients who had been taking NSAIDs before the trial stopped taking them when told that they were ulcerogenic. These patients had a lower recurrence rate than patients who had never taken NSAIDs. This suggests that in these patients gastric ulcer development may be linked to NSAIDs and that they therefore do better, when the offending agent is withdrawn, than patients in whom the gastric ulcer developed because of other factors. Scarring deformation and narrowing of the pylorus also appeared to favour recurrence; this may be related to claims that gastric retention due to outlet obstruction may play a part in certain forms of gastric ulcer.5253 Like others, we found no increased recurrence rate in patients who consumed alcohol,5' in older patients,4 50 5' in men,4 50 
